Evidence map›Paper›PMID 42819129›Full record

ArticleJAMIA open2026

Advancing multi-database cohort studies: lessons learned from a studyathon in a pharmaceutical company.

Elif Inan-Eroglu, Daloha Rodriguez-Molina, Khaled Abdelgawwad, Carina Dinkel-Keuthage, Montse Soriano Gabarró, Pareen Vora, Gianmario Candore, David Vizcaya, Katrin Manlik

Abstract readCase Reports
In one paragraph

Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elif Inan-ErogluPharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0001-9788-7266
Daloha Rodriguez-MolinaPharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0002-5355-0474
Khaled AbdelgawwadPharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0002-3596-6273
Carina Dinkel-KeuthagePharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0009-0003-2056-2713
Montse Soriano GabarróPharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0002-3825-0182
Pareen VoraPharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0002-5822-2453
Gianmario CandorePharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0002-7299-7300
David VizcayaPharmaceuticals, Global Medical & Evidence, Bayer Hispania SL, 08970 Sant Joan Despí, Spain.ORCID https://orcid.org/0000-0003-0248-7636
Katrin ManlikPharmaceuticals, Global Medical & Evidence, Bayer AG, 13353 Berlin, Germany.ORCID https://orcid.org/0000-0003-3647-5326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the feasibility and applicability of the studyathon format within a pharmaceutical company setting for generating reliable real-world evidence rapidly for a business-relevant research question. Materials and methods: Conducted at Bayer, the studyathon assessed recurrent events following a first-ever transient ischemic attack. It involved an 8-week preparatory phase, a 1-week execution phase, and a 3-week post-event phase, using multiple real-world data sources. Results: The studyathon concluded successfully with a conference abstract submission. Key learnings included the importance of defining precise research questions, organizational alignment, thorough preparation, and leveraging diverse expertise and skill sets. Discussion: The studyathon format proved suited for a pharmaceutical setting and revealed insights into its application. Our learnings highlight differences from multi-stakeholder community studyathons. Conclusion: The studyathon demonstrated its potential as a valuable research approach within a pharmaceutical company. It improved study timelines and cross-functional collaboration while preserving scientific rigor.

Indexed as

OHDSIOMOP common data modelreal-world datareal-world evidencestudyathon

Identifiers

PMID42819129
PMCPMC13625018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.